Management of malignant glioma - Quo vadis?

Onkologie

Volumn 31, Issue 6, 2008, Pages 300-302

  Stupp, Roger ^a   Hottinger, Andreas F ^b  

^a UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CILENGITIDE; IRINOTECAN; LOMUSTINE; METHYLGUANINE METHYLTRANSFERASE; METHYLTRANSFERASE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; CHROMOSOME 1P; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; OLIGODENDROGLIOMA; OVERALL SURVIVAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; GLIOMA; HUMANS; TREATMENT OUTCOME;

EID: 45249101555     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000134024     Document Type: Editorial

References (26)

1. Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide in the treatment of brain tumors. Lancet Oncol 2001;2:552-560.
2. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ: Phase i trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-4367.
3. Stupp R, Dietrich P, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff R, Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-1382.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
5. Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, Antonadou D, Saris G, Beroukas K, Karageorgis P: Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005;23:2372-2377.
6. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R: Clinical trial substantiates the predictive value of o-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-1874.
7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: Mgmt gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
8. Yaman E, Buyukberber S, Uner A, Coskun U, Muge A, Benekli M, Yamac D, Ozturk B, Osman Kaya A, Yildiz R, Ozkan S, Gunel N: Temozolomide in newly diagnosed malignant gliomas administered concomitantly with radiotherapy, and thereafter as consolidation treatment. 2008 2008;31: DOI: 10.1159/000127252.
9. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R: Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the eortc 26981/22981-ncic ce3 phase III randomized trial. J Clin Oncol 2006;24:2563-2569.
10. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R: Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of eortc and ncic trial 26981-22981/ce.3. Lancet Oncol 2008;9:29-38.
11. Brandes A, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E: Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro Oncol 2008 Apr 9. [Epub ahead of print].
12. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-461.
13. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE: Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82:81-83.
14. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M: MGMT promoter methylation status can predict the incidence and outcome of pseudo-progression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192-2197.
15. Stupp R, Hegi ME: Methyl-guanine methyltransferase testing in glioblastoma: When and how? J Clin Oncol 2007;25:1459-1460
16. (+ correspondence: J Clin Oncol. 2007 1410;1425(1423):3550; author reply 3550-1451).
17. van den Bent M, Brandes A, Rampling R, Kouwenhoven M, Kros J, Carpentier A, Clement P, Klughammer B, Lacombe D, Gorlia T: Randomized phase II trial of erlotinib versus temozolomide or BCNU in recurrent glioblastoma multiforme: EORTC 26034. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007;25 (suppl):76s (abstr #2004).
18. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259.
19. Cloughesy T, Prados M, Wen PY, Mikkelson T, Abrey L, Schiff D, Yung W, Paleologos N, Nicholas M, Dorr A, Zheng M, Dimery I, Friedman H: A phase II, randomized, non-comparative clinical trial of bevacizumab alone or in combination with cpt-11 prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma. Proc Society of Neuro-Oncology, Dallas 2007.
20. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM: Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988-994.
21. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC: A t(1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-9861.
22. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup radiation therapy oncology group trial 9402. J Clin Oncol 2006;24:2707-2714.
23. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized european organisation for research and treatment of cancer phase III trial. J Clin Oncol 2006;24:2715-2722.
24. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T: Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008
25. Stupp R, Goldbrunner R, Neyns B, Schlegel U, Clement P, Grabenbauer G, Hegi M, Nippgen J, Picard M, Weller M: Phase I/IIa trial of cilengitide (emd121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007;25 (suppl):75s (abstr #2000).
26. Stupp R, Hegi ME, Gilbert MR, Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127-4136.